PROCHLORPERAZINE EDISYLATE (PROCHLORPERAZINE EDISYLATE)
- Nausea and vomiting
- Cancer chemotherapy-induced nausea and vomiting
10 mg/2 mL (5 mg/mL) injection solution
- Inject 1 milliliter (5 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 3-4 hours as needed
5 mg/mL injection solution
- Inject 1 milliliter (5 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 3-4 hours as needed
Cancer chemotherapy-induced nausea and vomiting
- Inject 1 milliliter (5 mg) by intravenous route every 4 hours as needed for nausea and vomiting
- Inject 1 milliliter (5 mg) by intravenous route every 4 hours
- Inject 2 milliliters (10 mg) by intravenous route prior to chemotherapy and every 4 to 6 hours as needed at a rate not to exceed 5 mg/minute. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) by intravenous route prior to chemotherapy and every 4 hours at a rate not to exceed 5 mg/minute. Total dosageshould not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) by intravenous route prior to chemotherapy and every 6 hours at a rate not to exceed 5 mg/minute.
Nausea and vomiting
- Inject 1 milliliter (5 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 3-4 hours as needed
- Inject 1 milliliter (5 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 3 hours
- Inject 1 milliliter (5 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 4 hours
- Inject 1 milliliter (5 mg) by intramuscular route deeply into the upper outer quadrant of the buttock. If necessary, repeat every 3 or 4 hours. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 1 milliliter (5 mg) by intramuscular route 1 to 2 hours beforeinduction of anesthesia (may repeat once in 30 minutes), or to control acute symptoms during and after surgery (may repeat once)
- Inject 2 milliliters (10 mg) by intramuscular route 1 to 2 hours before induction of anesthesia (may repeat once in 30 minutes), or to control acute symptoms during and after surgery (may repeat once)
- Inject 2 milliliters (10 mg) by intramuscular route deeply into the upper outer quadrant of the buttock. If necessary, repeat every 3 or 4 hours. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) by intravenous route every 3-4 hours as needed at a rate not to exceed 5 mg/minute. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) by intravenous route every 3 hours at a rate not to exceed 5 mg/minute. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) by intravenous route every 4 hours at a rate not to exceed 5 mg/minute. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 3-4 hours as needed. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 3 hours . Total dosage shouldnot exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) deeply into the upper outer quadrant of the buttock by intramuscular route every 4 hours . Total dosage shouldnot exceed 40 mg in 24Hrs.
- 12.5 milliliters (50 mg) by oral route once daily in the evening
- Inject 0.5 milliliter (2.5 mg) by intravenous route every 3-4 hours as needed
- Inject 0.5 milliliter (2.5 mg) by intravenous route every 3 hours
- Inject 0.5 milliliter (2.5 mg) by intravenous route every 4 hours
Prevention of chemotherapy-induced nausea and vomiting
- Inject 1 milliliter (5 mg) by intravenous route every 4 hours as needed for nausea and vomiting
- Inject 1 milliliter (5 mg) by intravenous route every 4 hours
- Inject 2 milliliters (10 mg) by intravenous route prior to chemotherapy and every 4 to 6 hours as needed at a rate not to exceed 5 mg/minute. Total dosage should not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) by intravenous route prior to chemotherapy and every 4 hours at a rate not to exceed 5 mg/minute. Total dosageshould not exceed 40 mg in 24Hrs.
- Inject 2 milliliters (10 mg) by intravenous route prior to chemotherapy and every 6 hours at a rate not to exceed 5 mg/minute.
- dofetilide
- Orap
- pimozide
- Tikosyn
Contraindicated
- cabergoline
Severe
Moderate
- Alagesic Lq
- amobarbital
- Amytal
- Aplenzin
- Ascomp With Codeine
- Belladonna-phenobarbital
- Bupap
- Buproban
- bupropion HBr
- bupropion HCl
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- codeine-butalbital-ASA-caff
- deferoxamine
- Desferal
- Donnatal
- Esgic
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- Forfivo Xl
- Luminal
- Margesic
- Marten-tab
- Mysoline
- Nembutal Sodium
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- primidone
- secobarbital sodium
- Seconal Sodium
- Tencon
- Wellbutrin
- Wellbutrin Sr
- Wellbutrin Xl
- Zebutal
- Zyban
- Coma
- Neuroleptic malignant syndrome
- Stupor
Contraindicated
- Acute myocardial infarction
- Benign prostatic hyperplasia with lower urinary tract sx
- Carcinoma of breast
- Cardiac arrhythmia
- Congenital long QT syndrome
- Disease of liver
- Extrapyramidal disease
- Glaucoma
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Metabolic syndrome X
- Myocardial ischemia
- Organophos insecticide poisoning
- Pregnancy
- Prolonged QT interval
- Senile dementia
- Tardive dyskinesia
- Torsades de pointes
- Urinary retention
Severe
Moderate
- Alcoholism
- Anemia
- Angina
- Bradycardia
- Chronic disease of respiratory system
- Chronic heart failure
- Hyperglycemia
- Hyperprolactinemia
- Leukopenia
- Neutropenic disorder
- Obesity
- Orthostatic hypotension
- Parkinsonism
- Predisposition to aspiration
- Seizure disorder
- Thrombocytopenic disorder
- Weight gain
PROCHLORPERAZINE EDISYLATE (PROCHLORPERAZINE EDISYLATE)
- Nausea and vomiting
- Cancer chemotherapy-induced nausea and vomiting
- Akathisia
- Blurred vision
- Extrapyramidal disease
- Hypotension
- Pigmentary retinopathy
- Syncope
- Tardive dyskinesia
- Constipation
- Decreased sweating
- Dizziness
- Drowsy
- Nasal congestion
- Orthostatic hypotension
- Sialorrhea
- Xerostomia
More Frequent
Severe
Less Severe
- Contact dermatitis
- Dysuria
- Skin photosensitivity
- Abnormal sexual function
- Breast engorgement
- Galactorrhea not associated with childbirth
- Irregular menstrual periods
- Mastalgia
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Agranulocytosis
- Heat stroke
- Hypothermia
- Leukopenia
- Melanosis
- Neuroleptic malignant syndrome
- Neutropenic disorder
- Obstructive hyperbilirubinemia
- Priapism
- Prolonged QT interval
- Seizure disorder
- Torsades de pointes
- Visual changes
Less Severe
- Fever
- Photophobia
Contraindicated
Prochlorperazine
Do not use in pediatrics under 2 years of age or if child is under 20 lbs per manufacturer.
- 1 Day – 2 Years
- 1 Do not use in pediatrics under 2 years of age or if child is under 20 lbs per manufacturer.
Severe Precaution
None
Management or Monitoring Precaution
Prochlorperazine
Increased risk of extrapyramidal reactions. Avoid if suspected Reye syndrome.
- 2 Years – 18 Years
- Increased risk of extrapyramidal reactions. Avoid if suspected Reye syndrome.
Prochlorperazine
- Severity Level:
D
- Additional Notes: No fda category; neonatal complications( resp,gi,cns)w/exposure in 3rd trimester
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Prochlorperazine
Low amnt excr w/similar drug chlorpromazine, resulting in infant drowsiness
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Low amnt excr w/similar drug chlorpromazine, resulting in infant drowsiness |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Prochlorperazine
Neuro/Psych-Higher risk of tardive dyskinesia in the elderly. Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Increased risk of death in senile dementia. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | Y | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
Cancer chemotherapy-induced nausea and vomiting | |
R11.2 | Nausea with vomiting, unspecified |
Z51.11 | Encounter for antineoplastic chemotherapy |
Nausea and vomiting | |
R11 | Nausea and vomiting |
R11.2 | Nausea with vomiting, unspecified |
0-9 | A-Z |
---|---|
R11 | Nausea and vomiting |
R11.2 | Nausea with vomiting, unspecified |
R11.2 | Nausea with vomiting, unspecified |
Z51.11 | Encounter for antineoplastic chemotherapy |